Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
9.67
0.00 (0.00%)
May 12, 2026, 9:34 AM EDT - Market open
Prothena Corporation Revenue
Prothena Corporation had revenue of $51.08M in the quarter ending March 31, 2026, with 1,706.36% growth. This brings the company's revenue in the last twelve months to $57.94M, down -57.99% year-over-year. In the year 2025, Prothena Corporation had annual revenue of $9.68M, down -92.83%.
Revenue (ttm)
$57.94M
Revenue Growth
-57.99%
P/S Ratio
8.74
Revenue / Employee
$864,776
Employees
67
Market Cap
506.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | -125.47M | -92.83% |
| Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
| Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
| Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
| Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
| Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
| Dec 31, 2019 | 814.00K | -141.00K | -14.76% |
| Dec 31, 2018 | 955.00K | -26.56M | -96.53% |
| Dec 31, 2017 | 27.52M | 26.46M | 2,508.44% |
| Dec 31, 2016 | 1.06M | -552.00K | -34.35% |
| Dec 31, 2015 | 1.61M | -49.25M | -96.84% |
| Dec 31, 2014 | 50.85M | 50.18M | 7,422.78% |
| Dec 31, 2013 | 676.00K | -1.98M | -74.57% |
| Dec 31, 2012 | 2.66M | 2.15M | 424.26% |
| Dec 31, 2011 | 507.00K | -736.00K | -59.21% |
| Dec 31, 2010 | 1.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Valneva SE | 205.07M |
| XOMA Royalty | 52.15M |
| Prelude Therapeutics | 12.14M |
| Ovid Therapeutics | 7.25M |
| Ocugen | 4.47M |
| Upstream Bio | 2.85M |
| Shattuck Labs | 1.00M |
PRTA News
- 4 days ago - Prothena price target raised to $20 from $19 at Citizens - TheFly
- 4 days ago - Prothena cuts FY26 net cash used view to $18M-$23M from $50M-$55M - TheFly
- 4 days ago - Prothena Reports First Quarter 2026 Financial Results and Business Highlights - Business Wire
- 11 days ago - Prothena to Report First Quarter 2026 Financial Results on May 7 - Business Wire
- 14 days ago - Prothena announces Novo Nordisk obtained FDA fast track for PRX004 - TheFly
- 14 days ago - Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 4 weeks ago - Prothena names Annie Kingston as Chief Strategy Officer - TheFly
- 4 weeks ago - Prothena Announces Leadership Team Updates - Business Wire